Diabetes mellitus – factors that contribute to the occurrence, diagnosis and management of the disease

Milica Čizmić; Petar Ristić; Zorana Djuran; Jelena Karajović; Uroš  Zoranović; Nemanja Nenezić

doi:10.2298/VSP170620126C

Milica Čizmić Military Medical Academy, Department of Endocrinology, Belgrade, Serbia
Petar Ristić Military Medical Academy, Department of Endocrinology, Belgrade, Serbia
Zorana Djuran Military Medical Academy, Clinic of Endocrinology, Belgrade, Serbia
Jelena Karajović Military Medical Academy, Clinic of Endocrinology, Belgrade, Serbia
Uroš Zoranović Military Medical Academy, Department of Endocrinology, Belgrade, Serbia; University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
Nemanja Nenezić Military Medical Academy, Clinic of Endocrinology, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP170620126C

Keywords: diabetes mellitus, type 2;, vitamin d;, antibodies;, plasminogen activator inhibitor 1;, inflammation mediators.

References

Hao JB, Imam S, Dar P, Alfonso-Jaume M, Elnagar N, Jaume JC. Extreme insulin resistance from insulin antibodies (not insulin receptor antibodies) successfully treated with combination immunosuppressive therapy. Diabetes Care 2017; 40(2): e19–e20.

Maiza J, Caron-Debarle M, Vigouroux C, Schneebeli S. Anti-insulin receptor antibodies related to hypoglycemia in a previ-ously diabetic patient. Diabetes Care 2013; 36(6): e77.

Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Endocrine Society Evaluation and man-agement of adult hypoglycemic disorders: an Endocrine Socie-ty Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94(3): 709–28.

Talaei A, Mohamadi M, Adgi Z. The effect of vitamin D on in-sulin resistance in patients with type 2 diabetes. Diabetol Metab Syndr 2013; 5(1): 8.

Pittas AG, Dawson-Hughes B, Li T, Van DR, Willett WC, Man-son JE, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006; 29(3): 650–6.

Scragg R, Sowers MF, Bell C. Serum 25-hydroxyvitamin D, dia-betes and ethnicity in the third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27(12): 2813–8.

Jennersjö P, Guldbrand H, Björne S, Länne T, Fredrikson M, Lindström T, et al. A prospective observational study of all-cause mortality in relation to serum 25-OH vitamin D3 and parathyroid hormone levels in patients with type 2 diabetes. Diabetol Metab Syndr 2015; 7: 53.

de Boer IH. Vitamin D and glucose metabolism in chronic kid-ney disease. Curr Opin Nephrol Hypertens 2008; 17(6): 566–72.

Shet JJ, Shah A, Sheth FJ, Tivedi S, Lele M, Shah N, et al. Does vitamin D play a siglificant role in type 2 diabetes? BNC En-docr Disord 2015; 15: 5.

Ahmedieh H, Azar ST, Lakkis N, Arabi A. Hypovitaminosis D in patients with type 2 diabetes mellitus: A relation to disease control and complication. ISRN Endocrinol 2013; 2013: 641098.

Zoppini G, Galletti A, Targher G, Brangani C, Pichiri I, Trombetta M, et al. Lower levels of 25-hydroxyvitamin D3 are associated with a higher prevalence of microvascular complication in pa-tients with type 2 diabetes. BMJ Op Diab Res Car 2015; 3: 58.

Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mech-anisms for inflammatory damage in chronic disorders. QJM 2002; 95(12): 787–96.

Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, Valcheva P, Gracia O, Ibarz M, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012; 302(6): F647–57.

Li YC, Kong J, Wei M, Chen Z, Liu SQ, Cao L. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110(2): 229–38.

Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li JC. Combina-tion therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy. Blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 105(41): 15886–901.

Suzuki A, Kotake M, Ono Y, Kato T, Oda N, Hayakawa N, et al. Hypovitaminosis D in type 2 diabetes mellitus: Association with microvascular complications and type of treatment. En-docr J 2006; 53(4): 503–10.

Taverna MJ, Selam J, Slama G. Association between a protein polymorphism in the start codon of the vitamin D receptor gene and severe diabetic retinopathy in C-peptide-negative type 1 diabetes. J Clin Endocrinol Metab 2005; 90(8): 4803–8.

Inuki T, Fujiwara Y, Tayama K, Aso Y, Takemura Y. Alterations in serum levels of 1alfa, 25(OH)2D and osteocalcin in pa-tients wwith early diabetic nephropathy. Diab Res Clin Pract 2005; 38(1): 53–9.

Jee D, Han K, Kim EC. Inverse association between high blood 25-hydroxyvitamin D levels and diabetic retinopathy in a rep-resentative Korean population. PLoS One 2014; 9(12): e115199.

Basit A, Basit KA, Fawward A, Shaheen F, Fatima N, Petropoulos N, et al. Vitamin D for the treatment of painful diabetic neu-ropathy. BMJ Open Diabetes Res Care 2016; 4(1): e000148.

Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111(13): 1666–71.

Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006; 13(2): 101–7.

Shirai K, Song M, Suzuki J, Kurosu T, Oyama T, Nagayama D, et al. Contradictory effects of β1- and α1- aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI): CAVI independent of blood pressure. J Atheroscler Thromb 2011; 18(1): 49–55.

Suzuki J, Sakakibara R, Tomaru T, Tateno F, Kishi M, Ogawa E, Kurosu T, et al. Stroke and cardio-ankle vascular stiffness in-dex. J Stroke Cerebrovasc Dis 2013; 22(2): 171–5.

Miyoshi T, Doi M, Hirohata S, Sakane K, Kamikawa S, Kitawaki T, et al. Cardio-ankle vascular index is independently associat-ed with the severity of coronary atherosclerosis and left ven-tricular function in patients with ischemic heart disease. J Atheroscler Thromb 2010; 17(3): 249–58.

Kumagai T, Kasai T, Kato M, Naito R, Maeno K, Kasagi S, et al. Establishment of the cardio-ankle vascular index in patients with obstructive sleep apnea. Chest 2009; 136(3): 779–86.

Shirai K, Hiruta N, Song M, Kurosu T, Suzuki J, Tomaru T, et al. Cardio-ankle vascular index (CAVI) as a novel indicator of ar-terial stiffness: theory, evidence and perspectives. J Athero-scler Thromb 2011; 18(11): 924–38.

Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, et al. Inhibitory role of plasminogen activator inhibitor-1 in arte-rial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997; 96(9): 3180–91.

Carmeliet P, Moons L, Stassen JM, De Mol M, Bouché A, van den Oord JJ, et al. Vascular wound healing and neointima for-mation induced by perivascular electric injury in mice. Am J Pathol 1997; 150(2): 761–76.

Renckens R, Roelofs JJ, de Waard V, Florquin S, Lijnen R, Car-meliet P. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 2005; 3(5): 1018–25.

Gregory AD, Capoccia BJ, Woloszynek JR, Link DC. Systemic levels of G-CSF and interleukin-6 determine the angiogenic potential of bone marrow resident monocytes. J Leukoc Biol 2010; 88(1): 123–31.

Jin DK, Shido K, Kopp H, Petit I, Shmelkov SV, Young LM, et al. Cytokine-mediated deployment of SDF-1 induces revasculari-zation through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12(5): 557–67.

Oh CW, Hoover-Plow J, Plow EF. The role of plasminogen in an-giogenesis in vivo. J Thromb Haemost 2003; 1(8): 1683–734.

Murakami M, Simons M. Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol 2008; 15(3): 215–20.

Muhs BE, Plitas G, Delgado Y, Ianus I, Shaw JP, Adelman MA, et al. Temporal expression and activation of matrix metallo-proteinases-2, -9, and membrane type 1-matrix metallopro-teinase following acute hindlimb ischemia. J Surg Res 2003; 111(1): 8–15.

Magnusson PU, Dimberg A, Mellberg S, Lukinius A, Claesson-Welsh L. FGFR-1 regulates angiogenesis through cytokines in-terleukin-4 and pleiotrophin. Blood 2007; 110(13): 4214–22.